The Journal of
PHARMACOLOGY
And Experimental Therapeutics
A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2023 Vol. 385, No. 3

Contents

VIEWPOINT
Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder?
Ellen M. Unterwald and Scott M. Rawls

Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats
Michael R. Chojnacki, Eric B. Thorndike, John S. Partilla, Kenner C. Rice, Charles W. Schindler, and Michael H. Baumann

BEHAVIORAL PHARMACOLOGY
Assessment of Abuse-Related Discriminative Stimulus Effects of Nicotine Aerosol in Rodents
Yasmin Alkhlaif and Keith L. Shelton

Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats
Shyam H. Kamble, Samuel Obeng, Francisco León, Luis F. Restrepo, Tamara I. King, Erin C. Berthold, Siva Rama Raju Kanumuri, Lea R. Games-Jimenez, Victoria L.C. Pallares, Avi Patel, Nicholas P. Ho, Aidan Hampson, Christopher R. McCurdy, Lance R. McMahon, Jenny L. Wilkerson, Abhisheak Sharma, and Takato Hiranita

DRUG DISCOVERY AND TRANSLATIONAL MEDICINE
TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, Kimio Tohyama, Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, and Haruhide Kimura

In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule ent-Verticilide
Daniel J. Blackwell, Abigail N. Smith, Tri Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S. Akers, Jeffrey N. Johnston, and Bjorn C. Knollmann

ENDOCRINE AND DIABETES
BI-Y, an Neuropilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of Retinopathies
Leo Thomas, Sarah Low, Gale Hansen, Remko A. Bakker, and Nina Zippel

ERRATUM
Correction to “Cannabinoid Tolerance in S426A/S430A x β-Arrestin 2 Knockout Double-Mutant Mice”

About the cover: BI-Y antagonizes the biological effects of Nrp-1, thus also Sema3A and partially VEGF, promoting revascularization and reducing hyperpermeability. See the article by Thomas et al. (dx.doi.org/10.1124/jpet.122.001473).

Supplemental material is available at jpet.aspetjournals.org.